However, no statistically significant differences were found in cancer-specific survival between SATB2-negative versus SATB2-positive SBA patients, nor between SBAs with a CK7−/CK20+/CDX2+ or with CRC-like immunoprofile versus the remaining SBAs. This evidence concerns the gene KRT7 and colorectal carcinoma.